Closing on Nov. 3: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors

Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc.

Sector: Pharmaceutical Preparations Region: WI, United States

: | OTC Markets: NVLT

Similar to: BioAlliance Pharma SA, Hutchison China MediTech Ltd., Guerbet SA

Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.

News & Analysis

You may also be interested in: